456 related articles for article (PubMed ID: 18848503)
21. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital.
Seiderer J; Göke B; Ochsenkühn T
Digestion; 2004; 70(1):3-9. PubMed ID: 15297773
[TBL] [Abstract][Full Text] [Related]
22. Colectomy rate in acute severe ulcerative colitis in the infliximab era.
Aratari A; Papi C; Clemente V; Moretti A; Luchetti R; Koch M; Capurso L; Caprilli R
Dig Liver Dis; 2008 Oct; 40(10):821-6. PubMed ID: 18472316
[TBL] [Abstract][Full Text] [Related]
23. [Efficacy of premedication with intravenous corticosteroids and antihistaminics in preventing infusion reactions to infliximab].
Bermejo F; López San Román A; Algaba A; van Domselaar M; Carneros JA; Rivero M; Piqueras B; Valer MP
Gastroenterol Hepatol; 2008 Dec; 31(10):629-32. PubMed ID: 19174078
[TBL] [Abstract][Full Text] [Related]
24. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
Rutgeerts P; Van Assche G; Vermeire S
Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
[TBL] [Abstract][Full Text] [Related]
25. Treatment with biologic therapies and the risk of cancer in patients with IBD.
Biancone L; Calabrese E; Petruzziello C; Pallone F
Nat Clin Pract Gastroenterol Hepatol; 2007 Feb; 4(2):78-91. PubMed ID: 17268543
[TBL] [Abstract][Full Text] [Related]
26. Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen.
Domènech E; Zabana Y; Mañosa M; Garcia-Planella E; Cabré E; Gassull MA
J Clin Gastroenterol; 2010 Jan; 44(1):34-7. PubMed ID: 19417683
[TBL] [Abstract][Full Text] [Related]
27. [Response to stopping azathioprine in Crohn's patients on combined treatment with infliximab].
Martín De Carpi J; Varea V
An Pediatr (Barc); 2009 Mar; 70(3):271-7. PubMed ID: 19409244
[TBL] [Abstract][Full Text] [Related]
28. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
Atzeni F; Ardizzone S; Sarzi-Puttini P; Colombo E; Maconi G; De Portu S; Carrabba M; Bianchi Porro G
Aliment Pharmacol Ther; 2005 Sep; 22(5):453-61. PubMed ID: 16128684
[TBL] [Abstract][Full Text] [Related]
29. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
[TBL] [Abstract][Full Text] [Related]
30. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.
Lichtenstein GR; Diamond RH; Wagner CL; Fasanmade AA; Olson AD; Marano CW; Johanns J; Lang Y; Sandborn WJ
Aliment Pharmacol Ther; 2009 Aug; 30(3):210-26. PubMed ID: 19392858
[TBL] [Abstract][Full Text] [Related]
31. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study.
Bernstein CN; Wajda A; Blanchard JF
Clin Gastroenterol Hepatol; 2008 Jan; 6(1):41-5. PubMed ID: 18063423
[TBL] [Abstract][Full Text] [Related]
32. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease.
Mamula P; Markowitz JE; Piccoli DA; Klimov A; Cohen L; Baldassano RN
Clin Gastroenterol Hepatol; 2007 Jul; 5(7):851-6. PubMed ID: 17544875
[TBL] [Abstract][Full Text] [Related]
33. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota.
Jess T; Loftus EV; Velayos FS; Harmsen WS; Zinsmeister AR; Smyrk TC; Schleck CD; Tremaine WJ; Melton LJ; Munkholm P; Sandborn WJ
Gastroenterology; 2006 Apr; 130(4):1039-46. PubMed ID: 16618397
[TBL] [Abstract][Full Text] [Related]
34. Psychological stress and inflammatory bowel disease: a follow-up study in parents who lost a child in Denmark.
Li J; Nørgard B; Precht DH; Olsen J
Am J Gastroenterol; 2004 Jun; 99(6):1129-33. PubMed ID: 15180736
[TBL] [Abstract][Full Text] [Related]
35. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease.
Moss AC; Fernandez-Becker N; Jo Kim K; Cury D; Cheifetz AS
Aliment Pharmacol Ther; 2008 Jul; 28(2):221-7. PubMed ID: 18485127
[TBL] [Abstract][Full Text] [Related]
36. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up.
Kohn A; Daperno M; Armuzzi A; Cappello M; Biancone L; Orlando A; Viscido A; Annese V; Riegler G; Meucci G; Marrollo M; Sostegni R; Gasbarrini A; Peralta S; Prantera C
Aliment Pharmacol Ther; 2007 Sep; 26(5):747-56. PubMed ID: 17697208
[TBL] [Abstract][Full Text] [Related]
37. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre.
Wee JS; Petrof G; Jackson K; Barker JN; Smith CH
Br J Dermatol; 2012 Aug; 167(2):411-6. PubMed ID: 22404545
[TBL] [Abstract][Full Text] [Related]
38. The incidence of inflammatory bowel disease in a rural region of Southern Germany: a prospective population-based study.
Ott C; Obermeier F; Thieler S; Kemptner D; Bauer A; Schölmerich J; Rogler G; Timmer A
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):917-23. PubMed ID: 18794607
[TBL] [Abstract][Full Text] [Related]
39. Infliximab for ulcerative colitis in children and adolescents.
McGinnis JK; Murray KF
J Clin Gastroenterol; 2008 Sep; 42(8):875-9. PubMed ID: 18645529
[TBL] [Abstract][Full Text] [Related]
40. Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis.
Gradel KO; Nielsen HL; Schønheyder HC; Ejlertsen T; Kristensen B; Nielsen H
Gastroenterology; 2009 Aug; 137(2):495-501. PubMed ID: 19361507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
